Cellectis Reports Q3 2026 Results; Announces Strategic Pivot to In Vivo Gene Editing
Cellectis S.A. reported a net loss of $101.1 million for the nine-month period ended September 30, 2026, compared to a net loss of $41.3 million in the prior-year period, as revenues declined 76% to $14.8 million driven by lower activity under the AstraZeneca collaboration. The company announced a strategic transformation to become an in vivo gene editing company focused on chronic diseases, exiting development of lasme-cel and eti-cel while advancing.HEAL-101 and.HEAL-201 programs. The company recognized $26.8...
Read source-backed brief